KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Travere Therapeutics (TVTX) Accumulated Depreciation & Amortization (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Accumulated Depreciation & Amortization for 11 consecutive years, with $60.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Depreciation & Amortization rose 39.46% year-over-year to $60.7 million, compared with a TTM value of $60.7 million through Dec 2025, up 39.46%, and an annual FY2025 reading of $60.7 million, up 39.46% over the prior year.
  • Accumulated Depreciation & Amortization was $60.7 million for Q4 2025 at Travere Therapeutics, up from $43.6 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $60.7 million in Q4 2025 and bottomed at $12.7 million in Q4 2021.
  • Average Accumulated Depreciation & Amortization over 5 years is $35.3 million, with a median of $38.5 million recorded in 2023.
  • The sharpest move saw Accumulated Depreciation & Amortization tumbled 48.14% in 2021, then surged 85.96% in 2023.
  • Year by year, Accumulated Depreciation & Amortization stood at $12.7 million in 2021, then skyrocketed by 62.55% to $20.7 million in 2022, then soared by 85.96% to $38.5 million in 2023, then grew by 13.04% to $43.6 million in 2024, then skyrocketed by 39.46% to $60.7 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for TVTX at $60.7 million in Q4 2025, $43.6 million in Q4 2024, and $38.5 million in Q4 2023.